Simplifying Global Compliance
Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs
Washington Drug Letter
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing